RG 6333
Alternative Names: CD19 X CD28 - Roche; RG-6333; RO-7443904Latest Information Update: 16 Aug 2024
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD19 antigen modulators; CD28 antigen modulators; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 16 Aug 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia, USA, Denmark, France, Italy, United Kingdom (SC) (Roche pipeline, August 2024)
- 16 Aug 2024 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in United Kingdom, Italy, France, Denmark, USA, Australia (IV) (Roche pipeline, August 2024)
- 17 Jul 2024 Roche terminates a phase I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in United Kingdom, Italy, France, Denmark, USA (SC) due to sponsor portfolio re-alignment (NCT05219513)